Sign In
Buy ADXS
$0.604
+0 (+0%)
At Close: May 01, 2026
Trending Penny Stocks to Buy in September? Check These 3 Out
03:15pm, Sunday, 29'th Aug 2021
Are these penny stocks on your September small-caps watchlist? The post Trending Penny Stocks to Buy in September?
MONMOUTH JUNCTION, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and comm
Popular Penny Stocks to Buy in 2021? Here's 4 You Should Know About
03:30pm, Sunday, 18'th Jul 2021
Why These 3 Penny Stocks Are Popular Among Traders Right Now The post Popular Penny Stocks to Buy in 2021? Here's 4 You Should Know About appeared first on Penny Stocks to Buy, Picks, News and Informa
Hot Penny Stocks to Buy Now? 6 Reopening Stocks To Watch In July 2021
12:45pm, Saturday, 17'th Jul 2021
Reopening penny stocks are showing momentum right now; here's 6 to watch The post Hot Penny Stocks to Buy Now? 6 Reopening Stocks To Watch In July 2021 appeared first on Penny Stocks to Buy, Picks, Ne
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Advaxis, Inc. - ADXS
09:00pm, Friday, 16'th Jul 2021
NEW YORK, July 16, 2021 /PRNewswire/-- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Act
Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
08:00am, Thursday, 15'th Jul 2021
Study in biochemically recurrent prostate cancer expands off-the-shelf ADXS-HOT program to second indication Study in biochemically recurrent prostate cancer expands off-the-shelf ADXS-HOT program to
Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit
04:01pm, Wednesday, 14'th Jul 2021
PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, toda
7 Top Penny Stocks to Watch That You Probably Haven't Heard Of
11:30am, Sunday, 11'th Jul 2021
Are you familiar with these hot penny stocks to watch? 7 to keep an eye on right now The post 7 Top Penny Stocks to Watch That You Probably Haven't Heard Of appeared first on Penny Stocks to Buy, Pick
ADVAXIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Advaxis, Inc. - ADXS
03:47pm, Wednesday, 07'th Jul 2021
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Advaxis, I
SHAREHOLDER ALERT: WeissLaw LLP Investigates Advaxis, Inc.
02:44pm, Tuesday, 06'th Jul 2021
NEW YORK, July 6, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Advaxis, Inc. ("Advaxis" or the "Comp
Top Biotech Penny Stocks to Buy This Week? 9 To Watch
02:35pm, Tuesday, 06'th Jul 2021
Biotech penny stocks continue to climb, which companies are on your watchlist? The post Top Biotech Penny Stocks to Buy This Week?
ADXS Stock Increases Over 30%: Why It Happened
01:00pm, Tuesday, 06'th Jul 2021
The stock price of Advaxis, Inc. (NASDAQ: ADXS) increased by over 30% during intraday trading. This is why it happened.
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
10:16am, Tuesday, 06'th Jul 2021
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the bi
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
06:00am, Tuesday, 06'th Jul 2021
– Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelod
Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update
04:05pm, Monday, 14'th Jun 2021
ADXS-503 Phase 1/2 trial data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA®
